Table 1.

Baseline characteristics and biomarker levels.

AssessmentPlacebo+MTXGolimumab + MTX
50 mg every 4 wks50 mg every 2 wks100 mg every 4 wks100 mg every 2 wks
Patients treated3437323335
  Sex, n (%) women26 (74.3)30 (85.7)23 (67.6)26 (76.5)27 (79.4)
  Age, median (IQR), yrs52.0 (46.0, 66.0)57.0 (50.0, 64.0)48.0 (41.0, 63.0)57.5 (47.0, 66.0)53.5 (45.0, 65.0)
  No. swollen joints (0–66), median (IQR)13 (10, 18)14 (10, 21)14 (7, 26)20 (12, 26)14 (11, 21)
  No. tender joints (0–68), median (IQR)22 (16, 38)28 (18, 40)28 (9, 42)32 (21, 44)22 (16, 32)
Biomarker levels
  IL-18, median (range), pg/ml12.1 (5.9, 87.1)13.6 (4.3, 78.0)11.7 7.0 (48.5)13.6 (6.8, 60.3)10.3 (4.6, 31.9)
  E-selectin, median (range), pg/ml44,077 (13,132, 80,537)46,291 (12,293, 270,911)46,129 (13,457, 125,653)57,276 (12,639, 140,479)44,705 (12,437, 148,044)
  MMP-9 median (range), pg/ml252,001 (32,093, 962,822)262,242 (23,455, 1.63 106)316,407 (75,197, 1.86 106)279,090 31,817, 1.12 106)291,702 (71,693, 886,152)
  TIMP-1, median (range), pg/ml307,049 (111,035, 498,369)247,559 (74,840, 524,029)257,727 (94,055, 601,486)212,751 (1200.0, 469,205)265,650 (35261, 751,407)
  SAA, median (range), pg/ml48,765 (1779.8, 3.56 106)57,682 (2717.8, 2 106)40,947 (122.0, 1.58 106)29,787 (122.0, 359,932)33,677 (3298.8, 3.31 106)
  CRP, mg/dl2.0 (1.3, 3.4)2.1 (1.2, 3.4)1.6 (0.9, 2.7)1.4 (0.9, 2.7)1.6 (1.0, 3.0)
  • CRP: C-reactive protein; IL-18: interleukin-18; IQR: interquartile range; MMP-9: matrix metalloproteinase 9; MTX: methotrexate; SAA: serum amyloid A; TIMP-1: tissue inhibitor of matrix metalloproteinase 1.